EUCTR2020-001188-96-FR进行中（未招募）1 期
Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial - COVIDAXIS
CHU de Saint Etienne0 个研究点目标入组 1,200 人开始时间: 2020年3月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Adult Healthcare workers (HCWs) (physicians, nurses, assistant nurses, dentists, physiotherapists, and midwives)
- •-HCWs involved at the time of enrolment in the care of patients with confirmed or suspected SARS-CoV-2 infection in hospital settings in outpatient care settings or in geriatric long-term care facilities
- •-HCWs tested negative for HIV
- •-HCW affiliated to the French health insurance system
- •-HCW women of childbearing age with an effective contraception (ethinylestradiol-containing contraceptive pills are not regarded as effective in the context of LPV/r treatment)
- •-Willing to comply to study design and the follow-up
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1200
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-HCWs with positive SARS-CoV-2 RT-PCR of nasopharyngeal swab at the inclusion visit.
- •-HCW with past history of confirmed SARS-CoV-2 infection
- •-HCW with positive SARS-CoV-2 serology at the inclusion visit (if the serology is available at inclusion time, if SARS-CoV-2 serology is not available, it will be a secondary exclusion criteria)
- •-HCW with comorbidities such as chronic HCV infection treated by direct antiviral drugs or with hypothyroidism that need hormonal substitution, or retinopathy or known to have hypercholesterolemia hypertriglyceridemia
- •-Pregnant HCW
- •-Breastfeeding HCW
- •-HCW taking comedications known to have interactions with LPV/r according to the official characteristics of the product
- •See sessions 4.3 Contraindications and 4.5 Interaction with other medicinal products and other forms of interaction
- •Lopinavir and ritonavir are both inhibitors of the P450 isoform CYP3A in vitro. Co-administration of LPV/r and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse reactions. LPV/r does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).
- •LPV/r has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation. This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products
- •-HCW taking comedications known to have interactions with hydroxychloroquine according to the official characteristics of the product
研究者
相似试验
进行中（未招募）
1 期
Preventative Drug Treatment for COVID-19 Infectious DiseaseCoronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001331-26-GBCambridge University Hospitals NHS Foundation Trust1,000
尚未招募
不适用
Will colchicine be useful as an agent to prevent SARS-CoV-2 infection in kidney failure patients who are on maintenance hemodialysis?CTRI/2021/05/033605CMC Fluid research Funding
终止
3 期
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare WorkersCOVID-19NCT04328285Centre Hospitalier Universitaire de Saint Etienne118
进行中（未招募）
1 期
PROphylaxis for paTiEnts at risk of COVID-19 infecTion - PROTECTEUCTR2020-004144-28-GBCambridge university Hosptials NHS Foundation Trust and University of Cambridge1,500
进行中（未招募）
2 期
Preventative treatment for patients at risk of COVID-19 infection (PROTECT)COVID-19 (SARS-CoV-2 infection) in dialysis, vasculitis, and kidney transplant patientsInfections and InfestationsISRCTN88057279Cambridge University Hospitals NHS Foundation Trust5,000